

# Hidden in Plain Sight: A Rare Cause of Hepatosplenic T-Cell Lymphoma

## Sindhu Chadalawada, MD, PGY-2<sup>1</sup>; Benny Liu, MD<sup>2</sup>; Christina Chou, MD<sup>2\*</sup>

<sup>1</sup> Department of Internal Medicine; <sup>2</sup> Division of Gastroenterology and Hepatology, Highland Hospital, Oakland, CA

## Introduction

- •Hepatosplenic T-Cell Lymphoma (HSTCL) is an aggressive subgroup of non-hodgkin's lymphoma
- Clonal expansion and infiltration of cytotoxic T-cells<sup>1,2</sup>
- Worldwide incidence is approximately 1.4% for the  $\gamma\delta$ variant and even less for the  $\alpha\beta$  phenotype<sup>1</sup>
- Features include constitutional B symptoms, cytopenias, elevated liver enzymes, hepatosplenomegaly, and lack of lymphadenopathy<sup>1,2</sup>
- We present a rare case of  $\alpha\beta$  variant of HSTCL in an elderly woman

## **Case Description**

79 year old female with past medical history of Type 2 Diabetes mellitus and hyperlipidemia presenting with generalized weakness and weight loss.

**Review of Systems:** Loss of appetite, weight loss

Medications: Atorvastatin, Metformin

Physical Exam: No stigmata of chronic liver disease

#### Labs:

- Viral Hepatitis A, B, C: negative
- Immunoglobulin G: negative
- Epstein Barr virus, Herpes simplex virus, Cytomegalovirus: negative
- Strongyloides antibody: negative
- Smooth muscle antibody, Anti-Liver kidney microsome antibody, Antimitochondrial antibody, Antinuclear antibody: negative

	Day 1	Day 3	Day 27
AST (U/L)	860	1419	222
ALT (U/L)	938	1048	97
ALP (U/L)	416	336	188
Total Bilirubin (mg/dL)	5.8	7.7	24.1
Platelets (10*3/mcl)	129	115	26
Albumin (g/dL)	4.1	3.7	2.1

AST: Aspartate aminotransaminase; ALT: Alanine aminotransaminase; ALP: Alkaline phosphatase



Figure 1. MRI Abdomen showing mild hepatosplenomegaly

Molecular testing confirmed the presence of monoclonal T-cell receptor (TCR) beta and gamma populations highly suggestive of hepatosplenic T-cell lymphoma with  $\alpha\beta$  phenotype.

- INR 1.1

Discussion	

- HSTCL is a rare disease entity with ambiguous presentations
- The median age of diagnosis is 34 and elevated liver enzymes can be seen in around 38-43% of  $\gamma\delta$  cases<sup>1</sup>
- Less than 40 reported cases of the  $\alpha\beta$  phenotype<sup>2</sup>
- $\alpha\beta$  phenotype is seen more in women over 50 years of age and has been associated with worse prognosis<sup>3</sup>
- Most cases occur de novo, affecting the liver, spleen, and bone marrow and approximately 20% of cases arise in a setting of immunosuppression, often associated with autoimmune disorders and inflammatory bowel disease
- Outcomes are poor with a 5 year survival of < 10% without bone marrow transplant<sup>1</sup>

## **Teaching Points**

- Albeit rare and difficult to diagnose, HSTCL should be considered on the differential for elevated liver enzymes.
- Early diagnosis is crucial for immediate induction chemotherapy

#### References

1. Pro, B., Allen, P., & Behdad, A. (2020). Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood, 136(18), 2018-2026.https://doi.org/10.1182/ blood.2019004118

2. Cohen, J., Hariton, E., Kothari, D., Pihan, G. A., & Robson, S. C. (2013). Hepatosplenic alpha/beta T-cell lymphoma masquerading as cirrhosis. Journal of gastrointestinal oncology, 4(2), 131–136. https://doi.org/10.3978/ j.issn.2078-6891.2013.017

3. Yabe M, Miranda RN, Medeiros LJ. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors

### Table 1. Liver function tests and additional laboratory data



Figure 2. Liver biopsy showing infiltrate of atypical T-cells with high Ki67 index and  $\alpha\beta$ positivity



